WASHINGTON — Pfizer may have been the first company to deliver on the promises of former President Trump’s Operation Warp Speed, but it was an exceedingly rocky road for the drugmaking giant and the administration’s team, according to a sweeping new book from a former official.
“Of all the companies in which we invested, Pfizer was both the least transparent and least collaborative,” writes Paul Mango, the federal health department’s deputy chief of staff under Trump.
About the Author Reprints
Create a display name to comment
This name will appear with your comment
